Literature DB >> 6156038

The zinc and copper content of blood leucocytes and plasma from patients with benign and malignant prostates.

F K Habib, T C Dembinski, S R Stitch.   

Abstract

Zinc and copper levels in plasma have been measured in 41 patients with benign prostatic hypertrophy and 44 patients with carcinoma of the prostate, 24 of whom were receiving some form of hormonal therapy. The zinc concentrations in the blood leucocytes of some of the patients were also examined. We were unable to detect any differences between the leucocyte zinc levels of the three groups examined. Similarly, plasma zinc levels were not affected by age or disease, whereas the plasma copper levels were significantly higher (p less than 0.01) in the benign and malignant categories (mean = 124 micrograms/100 ml) when compared to a younger normal population (mean = 84.0 micrograms/100 ml). Hormonal therapy induced a rapid rise in the plasma copper concentrations and a concomitant marginal fall in zinc levels of the carcinoma patients. The magnitude of these hormone-induced changes were dependent on the type of therapy prescribed to the patient.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6156038     DOI: 10.1016/0009-8981(80)90390-3

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  18 in total

1.  Disulfiram treatment facilitates phosphoinositide 3-kinase inhibition in human breast cancer cells in vitro and in vivo.

Authors:  Haijun Zhang; Di Chen; Jonathan Ringler; Wei Chen; Qiuzhi Cindy Cui; Stephen P Ethier; Q Ping Dou; Guojun Wu
Journal:  Cancer Res       Date:  2010-04-27       Impact factor: 12.701

2.  Evidence that Human Prostate Cancer is a ZIP1-Deficient Malignancy that could be Effectively Treated with a Zinc Ionophore (Clioquinol) Approach.

Authors:  Leslie C Costello; Renty B Franklin; Jing Zou; Michael J Naslund
Journal:  Chemotherapy (Los Angel)       Date:  2015-06

3.  Di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT) overcomes multidrug resistance by a novel mechanism involving the hijacking of lysosomal P-glycoprotein (Pgp).

Authors:  Patric J Jansson; Tetsuo Yamagishi; Akanksha Arvind; Nicole Seebacher; Elaine Gutierrez; Alexandra Stacy; Sanaz Maleki; Danae Sharp; Sumit Sahni; Des R Richardson
Journal:  J Biol Chem       Date:  2015-02-26       Impact factor: 5.157

Review 4.  Novel metals and metal complexes as platforms for cancer therapy.

Authors:  Michael Frezza; Sarmad Hindo; Di Chen; Andrew Davenport; Sara Schmitt; Dajena Tomco; Q Ping Dou
Journal:  Curr Pharm Des       Date:  2010-06       Impact factor: 3.116

5.  Zinc plasma levels in prostatic carcinoma and BPH.

Authors:  M Lekili; A Ergen; I Celebi
Journal:  Int Urol Nephrol       Date:  1991       Impact factor: 2.370

Review 6.  New uses for old copper-binding drugs: converting the pro-angiogenic copper to a specific cancer cell death inducer.

Authors:  Di Chen; Q Ping Dou
Journal:  Expert Opin Ther Targets       Date:  2008-06       Impact factor: 6.902

Review 7.  Discovering proteasomal deubiquitinating enzyme inhibitors for cancer therapy: lessons from rational design, nature and old drug reposition.

Authors:  Kush Patel; Zainab So Ahmed; Xuemei Huang; Qianqian Yang; Elmira Ekinci; Christine M Neslund-Dudas; Bharati Mitra; Fawzy Aem Elnady; Young-Hoon Ahn; Huanjie Yang; Jinbao Liu; Qing Ping Dou
Journal:  Future Med Chem       Date:  2018-08-01       Impact factor: 3.808

Review 8.  Resveratrol mobilizes endogenous copper in human peripheral lymphocytes leading to oxidative DNA breakage: a putative mechanism for chemoprevention of cancer.

Authors:  S M Hadi; M F Ullah; A S Azmi; A Ahmad; U Shamim; H Zubair; H Y Khan
Journal:  Pharm Res       Date:  2010-01-30       Impact factor: 4.200

9.  Synchrotron X-ray imaging reveals a correlation of tumor copper speciation with Clioquinol's anticancer activity.

Authors:  Raul A Barrea; Di Chen; Thomas C Irving; Q Ping Dou
Journal:  J Cell Biochem       Date:  2009-09-01       Impact factor: 4.429

10.  Serum-Zn-levels in prostatic cancer.

Authors:  A Feustel; R Wennrich; B Schmidt
Journal:  Urol Res       Date:  1989
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.